MedTrace Logo

GPX-100 in Treating Patients With Solid Tumors

NCT00003403 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-04-23

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

GPX-100

Sponsors & Collaborators

  • Gem Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Frederick J. Dechow, PhD · Gem Pharmaceuticals

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003403 on ClinicalTrials.gov